INTRODUCTION
Treatment options for patients with recurrent and/or metastatic thyroid carcinoma who are not amenable to curative surgery or radioactive iodine (RAI) therapy are limited. Sorafenib is an oral kinase inhibitor (RTKI) that has multiple targets, including v-Raf murine sarcoma viral oncogene homolog B (BRAF), vascular endothelial growth factor receptor 1 (VEGFR1), and VEGFR2. 1 Sorafenib was approved in 2013 by the US Food and Drug Administration for the treatment of radioactive iodine (RAI)-refractory thyroid cancer based on results from the DECISION trial. That phase 3 study demonstrated a statistically significant improvement in progression-free survival (PFS) over placebo. 2 However, the improvement in PFS was only 5 months, and there was no significant improvement in overall survival between the study arms. Furthermore, the response rate was only 12.2%, and stable disease for at least 6 months was reported in only 41.8% of patients.
Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR). Temsirolimus binds to an abundant intracellular protein (12-kDa FK506-binding protein ) and, in this way forms a complex that inhibits mTOR complex 1 (mTORC1) signaling. 3 The disruption of mTOR signaling suppresses the protein synthesis that regulates cell cycle progression 4 and angiogenesis. 5 In thyroid cells, mTORC1 activity is required for the proliferative effects of thyroidstimulating hormone (TSH) in vitro and in vivo. 6 Inhibition of mTORC1 also suppresses the growth of thyroid cancer cell lines in vitro. 7 Given the low activity of single-agent sorafenib and the role of mTOR in thyroid cell proliferation, we completed a phase 2 study to evaluate the efficacy of the combination of sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin.
MATERIALS AND METHODS
We completed a nonrandomized, phase 2 study at our institution, the Memorial Sloan Kettering Cancer Center, evaluating the efficacy of combined sorafenib and temsirolimus in patients with RAI-refractory thyroid cancer. The study was approved by the Institutional Review Board at the Memorial Sloan Kettering Cancer Center and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Written, informed consent was obtained from all patients before study entry by 1 of the investigators.
Patients
Patients were eligible if they had histopathologically confirmed thyroid cancer of follicular cell origin, which included papillary, follicular, Hurthle cell, or anaplastic histologies. Patients were required to have available pathology for BRAF mutational testing. The inclusion criteria were as follows: 1) surgically inoperable and/or recurrent/metastatic disease, 2) at least 1 measureable lesion according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0, 3) at least 1 lesion that was fluorodeoxyglucose-avid on a positron emission tomography scan with a maximum standard uptake value >3, 4) progressive disease, and 5) disease refractory to RAI uptake. RAI-refractory disease was defined as either 1) absent or insufficient RAI uptake in all lesions or in an index lesion, 2) disease progression after RAI treatment, or 3) fluorodeoxyglucose-avid lesions. 8 Major eligibility criteria also included an Eastern Cooperative Oncology Group functional status from 0 to 2 and normal metabolic function and hematopoiesis. Furthermore, participants were excluded for any recent, significant cardiovascular disease or thromboembolic events, untreated brain metastases, nonhealing wound, history of gastrointestinal perforation, or any predisposition to gastrointestinal perforation. Prior treatment with sorafenib (or other treatment) was permitted, but patients who had received prior treatment with mTOR inhibitors were excluded.
Study Treatment
On the basis of phase 1 results, participants received oral sorafenib 200 mg twice daily and intravenous temsirolimus 25 mg weekly. 9 A cycle was considered 4 weeks of treatment. After 6 cycles of treatment, participants and their physicians were given the option to decrease the frequency of temsirolimus to 3 weekly treatments during every 4-week cycle. Restaging studies were done every 2 cycles for the first year and then every 3 cycles after the first year. Serum thyroglobulin levels were measured every 2 cycles (except in patients who had a positive antibody to thyroglobulin).
Statistical Analysis
The primary objective was to determine the objective response rate to sorafenib and temsirolimus. Secondary objectives were to determine PFS and whether there was an association between response and BRAF mutation status. The safety and tolerability of this combination was an additional secondary endpoint.
An exact 1-stage, phase 2 design was used to assess the primary endpoint of the radiographic response rate (partial or complete responses according to RECIST 1.0 criteria) to combined sorafenib and temsirolimus, with a 15% response rate considered not promising and a 34% response rate considered promising. The probabilities of a Type I error (falsely accepting a nonpromising therapy) and Type II error (falsely rejecting a promising therapy) were set to 0.1 and 0.1, respectively. We planned to evaluate a total of 36 patients. If 9 of the 36 patients evaluated had a partial response (PR), then the regimen would be considered worthy of further investigation.
PFS was defined from the start of treatment until either disease progression or removal from the study. A post hoc analysis was done correlating changes in the thyroglobulin serum level between baseline and at about 8 weeks with the duration of time on treatment to determine whether this had any predictive value.
Testing for BRAF valine-to-glutamic acid substitution at codon 600 (V600E) mutations was done either by Sequenom (LabCorp, Burlington, NC) or polymerase chain reaction sequencing. 10 In 17 patients, testing for a RAS mutation was also done. In 4 patients, tumors also were tested using a next-generation sequencing clinical assay (MSK-IMPACT 11 ), which tests for 341 key cancer genes, including those along the phosphoinositide 3-kinase (PI3K)/mTOR/protein kinase B(AKT) pathway.
RESULTS

Patient and Tumor Characteristics
In total, 37 patients were eligible and enrolled on this study. One patient signed consent and was registered but subsequently died of disease progression before receiving treatment on study and was not included in the analysis. According to the protocol, this patient was replaced. Patient and tumor characteristics are summarized in Table  1 . Mutational testing for BRAF V600E mutation was performed on tumors of all enrolled patients, and 10 (28%) were positive (Table 1) . Testing for mutations along the PI3K/mTOR/AKT pathway only occurred in 4 patients, and only 1 had any mutation along this pathway.
The majority of patients on study had received prior systemic treatment with cytotoxic chemotherapy and/or targeted therapy for thyroid cancer (Table 1) . Of the 20 patients (56%) who received prior treatment, 9 received cytotoxic chemotherapy, 18 received targeted therapy, and 8 received both cytotoxic chemotherapy and targeted therapy. Six patients (17%) received prior sorafenib, and 16 (44%) received prior VEGF-targeted therapy. Fifteen of the 18 patients (some received more than a single line of treatment) who received prior targeted therapy did so on a clinical trial evaluating the following agents: VEGF trap (n 5 11), XL281 (a Raf kinase inhibitor; n 5 3), AZD6244 (a mitogen-activated protein kinase inhibitor; n 5 2), depsipeptide (n 5 1), PTC229 (eukaryotic translation initiation factor 1A extracted from strain PTC229) with docetaxel (n 5 1), and pazopanib (with paclitaxel; n 5 1). Ten patients received 2 or more lines of prior treatment.
Response Rate
Response rates are summarized in Tables 2-4 and in Figure 1 . The best response for all patients was determined for 30 patients. Six patients were not evaluable because they came off treatment before the first radiographic scan for reasons other than progression of disease, which included excessive toxicity (n 5 1), withdrawal of consent (n 5 3), and seeing other treatment (n 5 1). Eight patients (22%) had a PR, and no patients had a complete response. The median time to a PR according to RECIST criteria for the 8 patients was 5.1 months (range, 1.4-8.7 months). One patient had a PR that was not confirmed with repeat imaging before removal from the study for toxicity and thus was categorized as having stable disease as the best response. The majority of patients, specifically, 21 (58%), demonstrated stable disease. Only 1 patient had disease progression as the best response.
Patients who had not received prior systemic treatment were more likely to have a PR from combined sorafenib and temsirolimus compared who those who did receive prior systemic treatment (38% vs 10%). BRAF mutational status did not significantly correlate with response to treatment.
Five of the 6 patients who received prior sorafenib were evaluated for best response. One patient had a PR, and 4 had stable disease; the patient with a PR developed progressive disease after <3 months on sorafenib. According to RECIST 1.0 criteria, the maximum disease shrinkage in this patient was 251%, and he was on study for 22.5 months before the disease began to progress. Analysis of his tumor revealed a phosphatase and tensin homolog (pTEN) mutation. Histologic subtype was not associated with response to therapy (for a breakdown, see Table 4 ). One of 2 patients on the study who had anaplastic thyroid cancer had a PR to therapy. The median duration of treatment was 6.7 months (range, 0.5-63 months) ( Table 3 ). In total, 11 patients (30.5%) remained on the study for >1 year, and 5 (13.8%) remained on the study for >2 years. Six patients discontinued sorafenib before their removal from the study and continued on temsirolimus alone for a range of 1.1 to 38 months. Based on best response, the median treatment duration was 22.3 months (range, 6.7-63 months) for patients who had a PR and 7.4 months (range, 1.3-19.5 months) for those with stable disease. The 1 patient who had progressive disease as his best response was on study for 0.5 months. In addition, the median treatment duration was 3.3 months (range, 0.5-22.5 months) for patients who had received prior systemic treatment, 7.5 months (range, 1.1-22.5 months) for those who had received prior sorafenib, and 8.7 months (range, 0.7-63 months) for those who had not received prior systemic treatment.
Patients with BRAF V600E mutation were on study for a median of 5.2 months (range, 0.7-63 months), whereas those without BRAF V600E mutation were on study for a median of 6.7 months (range, 0.5-25.6 months). In 17 patients, tumors were tested for the presence of a RAS mutation. Six of these 17 patients (35%) had a RAS mutation. There was no significant difference in the time on treatment between the 2 groups, with a median time of 7.7 months in the RAS mutant cohort and 6.7 months in the RAS-negative cohort.
When we limited the analysis only to those patients who came off the study for disease progression (n 5 18), the median time on treatment was 15.2 months (range, 0.5-63 months). In this group, 6 of the 18 patients had a BRAF mutation, and the median time on treatment was 19.3 months versus 12.5 months for the BRAF wild-type group (P 5 .17; log-rank test).
One of 2 study patients who had anaplastic thyroid cancer and attained a PR to combination therapy was on study for 6.9 months. The tumor in this patient was negative for a BRAF mutation.
The PFS rate at 1 year was 30.5%. The median overall survival for all patients on the study was 24.6 months. The median overall survival for patients who had a PR, stable disease, and disease progression as their best response was 33.7, 24.0, and 1.2 months, respectively.
Change in Thyroglobulin Levels
Change in the serum thyroglobulin level from baseline was measured in 26 patients (excluding any who had positive thyroglobulin antibodies during the study or who did not have a second thyroglobulin test at 8 weeks on treatment). Comparing the baseline value with that obtained at 8 weeks, the median thyroglobulin change was an increase of 2% (ranging from a decrease of 84% to an increase of 183%). Twelve patients had a decrease in their first thyroglobulin level while receiving treatment compared with baseline. If the thyroglobulin level decreased by 10% (11 patients) at approximately 8 weeks on treatment, then there was no significant increase for the time on treatment (median, 8.6 months vs 6.7 months; P 5 .9; log-rank test). Of those 11 patients with decreased thyroglobulin levels, 2 (18%) had a PR and 9 (82%) had stable disease. Of the other 15 patients without this decrease, 4 (27%) had a PR.
Toxicity and Study Removal
Five patients (14%) came off the study because of toxicity parameters specified in the protocol. Six patients discontinued sorafenib because of toxicity without removal from study and were continued on single-agent temsirolimus. Of the 12 patients who withdrew consent, only 1 patient withdrew from the study because of side effects. However, 2 patients withdrew consent after discontinuing temsirolimus because of thrombocytopenia and chose not to remain on study with single-agent sorafenib. An additional 3 patients withdrew consent for symptomatic deterioration or functional decline, and 1 patient withdrew consent to receive palliative radiation therapy, which required an interruption of study treatment. Five patients withdrew consent for failure to achieve a response to treatment despite not meeting criteria for disease progression. In addition, 3 patients came off the study for clinical disease progression, and 2 were removed from the study at their physicians' discretion because of transaminitis and a nonhealing ulcer related to study treatment. Two patients died while on study: One died in her sleep while on the study from an unknown cause but had experienced an increasing failure to thrive that had started before she began treatment. She was on study for 2.1 months at the time of her death without reported toxicities. The other patient died from likely progressive, metastatic osseous disease, which caused vertebral compression deformities. This death occurred after the patient was on study for 25.9 months. Reasons for removal from the study are summarized in Table 5 . The toxicities experienced by the 5 patients in the study who withdrew because of predefined study parameters included bowel perforation (n 5 2), excessive fatigue (n 5 2), and pneumonitis (n 5 1). The median time on study for these 5 patients was 1.7 months (range, 0.7-3.0 months). In the patient who was removed from the study because of grade 4 bowel perforation, tumor was observed at the site of perforation at the time of surgical resection; therefore, this event was more likely because of disease rather than excessive toxicity. The other patient who was removed for bowel perforation had grade 2 toxicity that did not require surgical management. The most common grade 3 and 4 toxicities related to sorafenib and temsirolimus included hyperglycemia (n 5 7), fatigue (n 5 5), anemia (n 5 4), and oral mucositis (n 5 3). One of the 2 sudden deaths on study was categorized as possibly related to drug toxicity. Because there was no clear cause of death for the patient who died in her sleep and no autopsy was performed, it was reported as a possibly associated toxicity. A list of grade 3, 4, and 5 toxicities that were at least possibly related to treatment is provided in Table 6 . Twenty-two of 36 patients (61%) required a dose reduction in at least 1 of the drugs during the course of treatment. In addition, 23 patients (64%) experienced at least 1 grade 3 toxicity during the course of treatment.
DISCUSSION
Compared with historic data from single-agent sorafenib, the addition of an mTOR inhibitor to sorafenib appears to provide additional activity in patients with metastatic, RAI-refractory thyroid cancer. In first-line treatment on 2 separate phase 2 clinical trials and the registration phase 3 clinical trial, single-agent sorafenib produced response rates of 11% to 23%. 2, 12, 13 Specifically, in the randomized phase 3 DECISION trial, the response rate was 12.2% in the sorafenib group compared with 0.5% in the placebo group (P < .0001). 2 In our current study, the combination of sorafenib and temsirolimus produced a PR rate of 22%, and stable disease was the best response in more than one-half (58%) of all patients. Unlike the DECISION trial, this study included patients who had received prior systemic therapy, including sorafenib. In the subgroup of patients who received this combination in the first-line setting in the current study, PRs occurred in 38% of patients, and 56% had stable disease.
This trial also demonstrated a response to combination therapy in 2 patients who had previously received systemic chemotherapy and/or targeted therapy, including 1 patient who had progressed on sorafenib. What is not known is whether the benefit in this group was because of the addition of temsirolimus to sorafenib or temsirolimus alone. A single-agent mTORC1 inhibitor, however, reportedly produced a response rate of only 5% but had a PFS of 43 weeks.
14 However, the patient in our trial who had previously received sorafenib, who had a confirmed response, and who had the longest PFS did have a pTEN mutation.
The current results did not indicate that response to sorafenib and temsirolimus was correlated with BRAF mutational status. Because BRAF mutational status did not affect response, the benefit of sorafenib may be related to a target other that RAF. Similar findings have been reported elsewhere in thyroid cancer. 15 However, when we evaluated only those patients who were removed from the study for actual disease progression, there was a nonsignificant increase in the time on treatment of 6.8 months in those who had BRAF V600E mutations compared with those who had wild-type BRAF. Therefore, the presence of a BRAF mutation still may have some effect on treatment duration and should be explored further.
It should be noted that 1 of our 2 patients with anaplastic thyroid cancer had a durable objective response. This patient met criteria for a PR according to RECIST criteria after 1.6 months on combination treatment at the time of the first restaging scan and remained on study for 6.9 months. This patient did not harbor a BRAF V600E mutation. The patient was aged 81 years, which typically would be considered a poor risk factor, 16 and had previously received treatment with paclitaxel, pazopanib, and radiation therapy on Radiation Therapy Oncology Group trial RTOG0912 (with progression of disease at the time of initiating the study). Adverse events consisted of the known side effects for both agents. Overall, the side-effect profile of this combination was tolerable; and, other than hyperglycemia, the other grade 4 toxicities and deaths on study were not definitely related to adverse effects associated with the treatment. The percentage of patients requiring dose reductions (61%) or withdrawal (14%) because of adverse events was similar to previously reported percentages among patients who received sorafenib alone (66% and 19%, respectively), 2 suggesting a similar toxicity profile.
This study started before publication of results from the DECISION study and before US Food and Drug Administration approval of sorafenib for RAI-refractory thyroid cancer. Since this study's inception, there have been other studies in this disease, including a randomized phase 3 study comparing lenvatinib versus placebo in both the first-line and second-line setting (SELECT), which reported a response rate of 64.8% in the lenvatinibtreated group. 17 Other VEGF RTKIs that have been evaluated in the phase 2 setting include pazopanib (PR rate, 49%), 18 vandetanib (PR rate, 1%), 19 sunitinib (PR, rate 28%), 20 axitinib (PR, rate 31%), 21 and motesanib (PR, rate 14%). 22 With the exception of the SELECT study, none of the other studies treated patients who had received prior VEGF-directed treatment.
Although it is not appropriate to compare the activity of agents across separate studies, the PR rate of 38% observed in patients who did not receive prior VEGFdirected therapy with sorafenib and temsirolimus is favorable compared with the rates reported for most of the other VEGF RTKIs studied. In terms of the response rate and PFS, lenvatinib has the most favorable data to date of all of these VEGF RTKIs in both phase 2 23 and phase 3 17 studies. However, the published results for lenvatinib indicate no significant difference in PFS whether lenvatinib is used in the first line (median PFS, 18.7 months) or the second line (median PFS, 15.1 months). Because, to date, no other VEGF RTKI has produced similar activity in the second-line setting after the receipt of first-line lenvatinib, it is very reasonable to study treatment in the first-line setting that might not be as active as lenvatinib in patients with RAI-refractory thyroid cancer when the clinician can reasonable expect that the patient will be able to receive more than 1 line of therapy and will be able to receive lenvatinib in the second line.
CONCLUSION
Although the current study did not meet its a priori target of responses in 9 of the 36 patients who received combined sorafenib and temsirolimus, the statistics were set up before better data became available about the activity of sorafenib in thyroid cancer and in the absence of available data on previously treated patients. The sorafenib and temsirolimus combination appears to be active in patients with RAI-refractory thyroid cancer, producing impressive response rates in patients who received no prior treatment compared with historic data from single-agent sorafenib. Responses, along with durable disease stabilization, also were observed among patients who had received prior VEGF-targeted therapy, including sorafenib. The combination of sorafenib and temsirolimus in patients with RAI-refractory thyroid cancer is worthy of further investigation, particularly in comparisons with singleagent sorafenib. Finally, 1 of the 2 patients with anaplastic thyroid cancer in our study experienced a major response to sorafenib and temsirolimus, and this specific patient requires further assessment in future studies.
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